In the next step, we will carry out in vitro and in vivo experiments to explore the signaling pathway that inhibits NF-κB in regulating NAFLD, which will be beneficial to the development new molecular treatments for NAFLD. Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.